Work

Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™).

Year: 2017

Type: article

Study design: Study Protocol

Source: PubMed

Authors: Oliver Distler, Kevin K Brown, Jörg H W Distler, Shervin Assassi, Toby M Maher, Vincent Cottin, John Varga, Carl Coeck, Martina Gahlemann, Wiebke Sauter, Hendrik Schmidt, Kristin B Highland

Institutions: University Hospital Zurich, National Jewish Health, Friedrich-Alexander-Universität Erlangen-Nürnberg, The University of Texas Health Science Center at Houston, National Institute for Health and Care Research, Royal Brompton Hospital, Imperial College London, Lyon 1 Université, Hôpital Louis Pradel, Boehringer Ingelheim (Belgium), Boehringer Ingelheim (Switzerland), Boehringer Ingelheim (Germany), Cleveland Clinic

Language: English

Topic: Systemic Sclerosis and Related Diseases

Subfield: Rheumatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2907506804

FWCI: 11.91

Cites:

Cited by: 75

Related to: 10